Seth Lederman - Jun 29, 2022 Form 4 Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)

Role
Chief Executive Officer, Director
Signature
/s/ Seth Lederman
Stock symbol
TNXP
Transactions as of
Jun 29, 2022
Transactions value $
$34,200
Form type
4
Date filed
7/1/2022, 04:05 PM
Previous filing
Mar 28, 2022
Next filing
Feb 24, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TNXP Common Stock, $0.001 par value Purchase $34.2K +20K +472.26% $1.71 24.2K Jun 29, 2022 By IRA Account F1
holding TNXP Common Stock, $0.001 par value 3.51K Jun 29, 2022 Direct F1
holding TNXP Common Stock, $0.001 par value 1 Jun 29, 2022 By spouse F1
holding TNXP Common Stock, $0.001 par value 1 Jun 29, 2022 By Leder Laboratories, Inc. F1, F2
holding TNXP Common Stock, $0.001 par value 1 Jun 29, 2022 By Starling Pharmaceuticals, Inc. F1, F2
holding TNXP Common Stock, $0.001 par value 7 Jun 29, 2022 By Lederman & Co., LLC F1, F2
holding TNXP Common Stock, $0.001 par value 2 Jun 29, 2022 By L&L Technologies, LLC F1, F2
holding TNXP Common Stock, $0.001 par value 2 Jun 29, 2022 By Targent Pharmaceuticals, LLC F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares reported reflect a 1-for-32 reverse stock split effective May 17, 2022.
F2 Reporting person may be deemed to be a control person of this entity.